Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.35 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.33 |
| ▸ | TACR3 | P29371 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ERG | P11308 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347807 | 0.88 | AVPR1A (0.39) | BRD4KCNH2AVPR1A | |
| SCHEMBL3399961 | 0.85 | TNKS2 (0.39) | TNKS2TNKSTACR3CYP1A2CYP2C19 | |
| SCHEMBL3400041 | 0.85 | BRD4 (0.46) | TNKS2TNKSTGFBR1THRBMAPK14 | |
| SCHEMBL1347704 | 0.78 | TNKS2 (0.38) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL313995 | 0.77 | BRD4 (0.45) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL315096 | 0.75 | TNKS2 (0.34) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL313824 | 0.71 | TNKS2 (0.40) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL314350 | 0.71 | TNKS2 (0.40) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL314758 | 0.71 | TNKS2 (0.40) | TNKS2TNKSTGFBR1TACR3CYP1A2 | |
| SCHEMBL3226167 | 0.69 | TNKS2 (0.37) | TNKS2TNKSTACR3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | claimed |
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | disclosed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2008052628-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | TGFBR1, TGFBR2, ACVR1 | TNKS2 1141/4885TNKS 1101/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.